BACKGROUND:

Cervical cancer is a public health problem due to its high incidence. Its main cause is the human papillomavirus transmitted by sexual contact. One prevention tool is immunization. At present there are three vaccines, the nonavalent is the most recent.

OBJECTIVE:

To investigate the recent literature and describe the findings with the application of the nonavalent vaccine in patients with cervical cancer.

METHODOLOGY:

Search of articles in the Pubmed database with the descriptor “nonavalent” and the MeSH terms “recombinant nonavalent human papillomavirus vaccine”, “human papillomavirus vaccines” and “cervical cancer”; the above with adverse reactions, effectiveness and impact of the nonavalent vaccine against cervical cancer.

RESULTS:

We found 107 articles of which 80 were excluded due to duplicates, confusing titles and incomplete abstracts, without providing data related to the study. In the end, only 27 sources were analyzed.

CONCLUSIONS:

The nonavalent vaccine has reach against five high-risk genotypes; more than other vaccines. It is effective against diseases caused by human papillomavirus, including cervical intraepithelial neoplasia and cervical cancer. In addition, it has a safety profile similar to that of its predecessor vaccines, although its effectiveness is linked to other factors.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )